Loading
A phase 2 trial of Emapalumab in Multiple myeloma, run by NYU Langone Health, not yet recruiting.
Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS is a phase 2 interventional study registered as NCT07567014 by NYU Langone Health, with 60 participants planned, started 2026-05-11 and due to reach its primary completion in 2028-05-31. Interventions recorded: Emapalumab. Conditions recorded: Multiple Myeloma, Large B-cell Lymphoma (LBCL).
Linked to the drug Emapalumab because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Multiple myeloma and the tag pipeline.
Shares Emapalumab and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/